Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up

Annals of the Rheumatic Diseases

Volumn 75, Issue 1, 2016, Pages 30-36

  Mok, Chi Chiu ^a   Ying, King Yee ^b   Yim, Cheuk Wan ^c   Siu, Yui Pong ^a   Tong, Ka Hang ^a   To, Chi Hung ^a   Ng, Woon Leung ^c  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; ANTIINFLAMMATORY AGENT; CREATININE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ALOPECIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; GYNECOLOGIC INFECTION; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTRICHOSIS; INDUCTION CHEMOTHERAPY; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE CRAMP; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SINUSITIS; SKIN INFECTION; TINNITUS; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; TIME FACTOR; URINE; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CREATININE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; PROTEINURIA; RECURRENCE; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954401686     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206456     Document Type: Article

References (45)

1. Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:2774-82.
2. Bastian HM, Roseman JM, McGwin G Jr, et al.; LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60.
3. Mok CC, Tang SS. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 2004;117:791-5.
4. Appenzeller S, Clarke AE, Panopalis P, et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol 2009;36:947-52.
5. Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:2154-60.
6. Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis 1999;34:315-23.
7. Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355. e25-33.
8. Korbet SM, Schwartz MM, Evans J, et al. Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-54.
9. Hui M, Garner R, Rees F, et al. Lupus nephritis: a 15-year multi-centre experience in the UK. Lupus 2013;22:328-32.
10. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. New Engl J Med 1986;314:614-19.
11. Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
12. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
13. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7.
14. Mok CC, Chan PT, To CH. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum 2013;65:206-10.
15. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
16. Appel GB, Contreras G, Dooley MA, et al.; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al.; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75.
18. Krämer BK, Del Castillo D, Margreiter R, et al.; European Tacrolimus versus Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant 2008;23:2386-92.
19. Silva HT Jr, Yang HC, Meier-Kriesche HU, et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 2014;97:636-41.
20. Penninga L, Møller CH, Gustafsson F, et al. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 2010;66:1177-87.
21. Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of Tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus 2011;20:636-40.
22. Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 2008;47:1678-81.
23. Mok CC, Tong KH, To CH, et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005;68:813-17.
24. Lee T, Oh KH, Joo KW, et al. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus 2010;19:974-80.
25. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with Tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44.
26. Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or Tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012;27:1467-72.
27. Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19:2001-10.
28. Mok CC, To CH, Yu KL, et al. Combined low-dose mycophenolate mofetil and Tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus 2013;22:1135-41.
29. Yoon KH. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol 2010;2010:686480.
30. Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol 2010;159:199-207.
31. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-8.
32. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
33. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32.
34. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
35. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005;10:504-10.
36. Chen W, Liu Q, Chen W, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012;21:944-52.
37. Asamiya Y, Uchida K, Otsubo S, et al. Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clin Pract 2009;113:c330-6.
38. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
39. Hallegua D, Wallace DJ, Metzger AL, et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000;9:241-51.
40. Houssiau FA, D'Cruz D, Sangle S, et al.; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
41. Dooley MA, Jayne D, Ginzler EM, et al.; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
42. Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 2008;7:219-22.
43. Hebert MF, Zheng S, Hays K, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation 2013;95:908-15.
44. Webster P, Wardle A, Bramham K, et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 2014;23:1192-6.
45. Bertsias GK, Tektonidou M, Amoura Z, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.